Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera-Reference-Cited by-同舟云学术

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

Published:2008-04 Issue:4 Volume:13 Page:311-320
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Wernig Gerlinde,Kharas Michael G.,Okabe Rachel,Moore Sandra A.,Leeman Dena S.,Cullen Dana E.,Gozo Maricel,McDowell Elizabeth P.,Levine Ross L.,Doukas John,Mak Chi Ching,Noronha Glenn,Martin Michael,Ko Yon D.,Lee Benjamin H.,Soll Richard M.,Tefferi Ayalew,Hood John D.,Gilliland D. Gary

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference23 articles.

1. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta;Apperley;N. Engl. J. Med.,2002

2. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

3. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome;Cools;N. Engl. J. Med.,2003

4. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome;Druker;N. Engl. J. Med.,2001

5. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia;Druker;N. Engl. J. Med.,2001

Cited by 345 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors;European Journal of Medicinal Chemistry;2024-09

2. The JAK-STAT pathway: from structural biology to cytokine engineering;Signal Transduction and Targeted Therapy;2024-08-21

3. Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors;Bioorganic Chemistry;2024-08

4. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis;Blood;2024-06-06

5. Janus Kinases and Autoimmunity: Bridging Pathways to Therapy;International Journal of Drug Discovery and Pharmacology;2024-06-05